Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Regeneron stock touches 52-week low at $666 amid market shifts ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in global sales, which consisted ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has reached its 52-week low, trading at $785.31.This price level reflects a subtle yet notable decline of 0.43% over the past year, indicating a ...

Regeneron stock touches 52-week low at $785.31 Open in App Get 50% Off Sign In Free Sign Up ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...